As of 2026-09-25, the EV/EBITDA ratio of Foghorn Therapeutics Inc. (FHTX) is -2.44. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FHTX's latest enterprise value is 159.13 mil USD. FHTX's TTM EBITDA according to its financial statements is -65.27 mil USD. Dividing these 2 quantities gives us the above FHTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.9x - 17.0x | 16.6x |
| Forward P/E multiples | 18.7x - 20.8x | 19.3x |
| Fair Price | (19.63) - (17.76) | (18.80) |
| Upside | -607.2% - -559.0% | -585.7% |
| Date | EV/EBITDA |
| 2026-09-23 | -2.44 |
| 2026-09-22 | -2.77 |
| 2026-09-21 | -2.69 |
| 2026-09-18 | -2.68 |
| 2026-09-17 | -2.73 |
| 2026-09-16 | -2.71 |
| 2026-09-15 | -2.66 |
| 2026-09-14 | -2.88 |
| 2026-09-11 | -2.93 |
| 2026-09-10 | -3.00 |
| 2026-09-09 | -3.16 |
| 2026-09-08 | -3.30 |
| 2026-09-04 | -3.38 |
| 2026-09-03 | -3.34 |
| 2026-09-02 | -3.61 |
| 2026-09-01 | -4.08 |
| 2026-08-31 | -4.12 |
| 2026-08-28 | -4.35 |
| 2026-08-27 | -4.55 |
| 2026-08-26 | -4.97 |
| 2026-08-25 | -5.12 |
| 2026-08-24 | -5.14 |
| 2026-08-21 | -5.32 |
| 2026-08-20 | -5.26 |
| 2026-08-19 | -5.31 |
| 2026-08-18 | -5.03 |
| 2026-08-17 | -5.02 |
| 2026-08-14 | -4.59 |
| 2026-08-13 | -4.79 |
| 2026-08-12 | -4.93 |
| 2026-08-11 | -4.88 |
| 2026-08-10 | -4.57 |
| 2026-08-07 | -4.42 |
| 2026-08-06 | -3.97 |
| 2026-08-05 | -3.35 |
| 2026-08-04 | -3.33 |
| 2026-08-03 | -3.10 |
| 2026-07-31 | -3.03 |
| 2026-07-30 | -3.22 |
| 2026-07-29 | -3.22 |
| 2026-07-28 | -3.57 |
| 2026-07-27 | -3.63 |
| 2026-07-24 | -3.32 |
| 2026-07-23 | -3.52 |
| 2026-07-22 | -3.64 |
| 2026-07-21 | -3.60 |
| 2026-07-20 | -3.63 |
| 2026-07-17 | -3.63 |
| 2026-07-16 | -3.52 |
| 2026-07-15 | -3.86 |